Document is current
Any future updates will be listed below
-
Authors
Ma, Jian https://orcid.org/0000-0001-9794-4689
Li, Lei https://orcid.org/0000-0001-6199-8263
Ma, Bohan
Liu, Tianjie https://orcid.org/0000-0002-2321-1869
Wang, Zixi
Ye, Qi
Peng, Yunhua https://orcid.org/0000-0001-8814-2801
Wang, Bin
Chen, Yule
Xu, Shan
Wang, Ke
Dang, Fabin https://orcid.org/0000-0002-1954-8231
Wang, Xinyang
Zeng, Zixuan
Jian, Yanlin
Ren, Zhihua
Fan, Yizeng
Li, Xudong
Liu, Jing https://orcid.org/0000-0002-3113-4015
Gao, Yang
Wei, Wenyi
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81925028, 82230097, 82173037, 82273106)
National Key R&D Program of China
- License Information
-
More Information
Article History
Received: 24 June 2023
Accepted: 5 February 2024
First Online: 29 February 2024
Competing interests
: W.W. is a co-founder and consultant for the ReKindle Therapeutics. Z.R. is the VP of Kintor Pharmaceutical, Inc. Other authors declare no competing interests.
: The study protocol of clinical samples for bladder cancer tissue microarray slides was approved by the Institutional Ethics Committee of Shanghai Outdo Biotech Company. All patients provided written informed consent to participate in the study. The mini PDX model protocol was approved by the Institutional Ethics Committee of Shanghai LIDE Biotech.
